The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy. Issue 5 (28th November 2021)

• Record Type: Journal Article
• Authors: Williams, Cheyenne; Khondakar, Nabila R.; Daneshvar, Michael A.; O'Connor, Luke P.; Gomella, Patrick T.; Mehralivand, Sherif; Yerram, Nitin K.; Egan, Jillian; Gurram, Sandeep; Rompré-Brodeur, Alexis; Webster, Bradley R.; Owens-Walton, Jeunice; Parnes, Howard; Merino, Maria J.; Wood, Bradford J.; Choyke, Peter; Turkbey, Baris; Pinto, Peter A.
• Is Part Of: Journal of urology. Volume 206:Issue 5(2021)
• Page Start: 1157
• Page End: 1165
• Publication Date: 2021-11-28
• Subjects: multiparametric magnetic resonance imaging -- prostatic neoplasms -- watchful waiting; Genitourinary organs -- Periodicals; Urology -- Periodicals; Urology -- Periodicals; Urologie -- Périodiques; Urologie; 616.6
• DOI: 10.1097/JU.0000000000001941
• Languages: English
• ISSNs: 0022-5347

Abstract

Abstract : Purpose: We sought to evaluate whether bilateral prostate cancer detected at active surveillance (AS) enrollment is associated with progression to Grade Group (GG) ≥2 and to compare the efficacy of combined targeted biopsy plus systematic biopsy (Cbx) vs systematic biopsy (Sbx) or targeted biopsy alone to detect bilateral disease. Materials and Methods: A prospectively maintained database of patients referred to our institution from 2007–2020 was queried. The study cohort included all AS patients with GG1 on confirmatory Cbx and followup of at least 1 year. Cox proportional hazard analysis identified baseline characteristics associated with progression to ≥GG2 at any point throughout followup. Results: Of 579 patients referred, 103 patients had GG1 on Cbx and were included in the study; 49/103 (47.6%) patients progressed to ≥GG2, with 30/72 (41.7%) patients with unilateral disease progressing and 19/31 (61.3%) patients with bilateral disease progressing. Median time to progression was 68 months vs 52 months for unilateral and bilateral disease, respectively (p=0.006). Both prostate specific antigen density (HR 1.72, p=0.005) and presence of bilateral disease (HR 2.21, p=0.012) on confirmatory biopsy were associated with AS progression. At time of progression, GG and risk group were significantly higher in patients with bilateral versus unilateral disease. Cbx detected 16% more patients with bilateral disease than Sbx alone. Conclusions: Bilateral disease and prostate specific antigen density at confirmatory Cbx conferred greater risk of earlier AS progression. Cbx was superior to Sbx for identifying bilateral disease. AS risk-stratification protocols may benefit from including presence of bilateral disease and should use Cbx to detect bilateral disease.